RNA transfection

IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages

Retrieved on: 
Thursday, December 1, 2022

PLACCINE is IMUNONs non-viral, non-device plasmid DNA-based vaccine modality targeting multiple antigens from a single vector.

Key Points: 
  • PLACCINE is IMUNONs non-viral, non-device plasmid DNA-based vaccine modality targeting multiple antigens from a single vector.
  • In addition, the data presented showed that IMUNONs plasmid DNA vaccine yielded comparable yet more durable antigen expression than either the protein or a commercial mRNA vaccine.
  • We are delighted to share preclinical proof of concept along with highlighting key competitive advantages to a global audience of vaccine and immunotherapy leaders, said Dr. Corrine Le Goff, IMUNONs President and Chief Executive Officer.
  • IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

ReCode Therapeutics Appoints Trisha Millican to Board of Directors

Retrieved on: 
Thursday, December 1, 2022

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of Patricia Trisha Millican to the companys Board of Directors.

Key Points: 
  • ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of Patricia Trisha Millican to the companys Board of Directors.
  • On behalf of ReCodes leadership team and Board, I am delighted to welcome Trisha Millican to our Board of Directors, said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer and a board member of ReCode Therapeutics.
  • Currently, Ms. Millican is a strategic advisor to various life science companies and serves on the board of directors of Life Science Cares, San Diego.
  • ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics.

Cardior Welcomes Dr. Orly Vardeny as Permanent Guest to the Board

Retrieved on: 
Thursday, December 1, 2022

Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest.

Key Points: 
  • Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest.
  • Her deep understanding of all stages of clinical development and the challenges of adopting new therapies into the current treatment landscape will be of significant importance to Cardior.
  • The addition of Orly to the Board of Directors reflects Cardiors commitment to deliver a breakthrough for the current standard of care for heart diseases.
  • Orly Vardeny, PharmD, MS, is an Associate professor of Medicine at the University of Minnesota.

ESPEROVAX SIGNS EXCLUSIVE LICENSING AGREEMENT WITH THE UNIVERSITY OF MICHIGAN FOR A NOVEL MANUFACTURING TECHNOLOGY FOR THE PRODUCTION OF VACCINES AND THERAPEUTICS

Retrieved on: 
Wednesday, November 30, 2022

ANN ARBOR, Mich., Nov. 30, 2022 /PRNewswire/ -- Esperovax, a leading developer of oral vaccines, today announced it has signed a new, exclusive licensing agreement with Innovation Partners at the University of Michigan to produce vaccines and therapeutics using a novel yeast-based manufacturing method. This next-generation manufacturing technology will accelerate current programs to the clinic by allowing for a continuous purification process. In turn, such vaccines can be purified and produced with higher yields at optimal cost.

Key Points: 
  • ANN ARBOR, Mich., Nov. 30, 2022 /PRNewswire/ -- Esperovax, a leading developer of oral vaccines, today announced it has signed a new, exclusive licensing agreement with Innovation Partners at the University of Michigan to produce vaccines and therapeutics using a novel yeast-based manufacturing method.
  • This next-generation manufacturing technology will accelerate current programs to the clinic by allowing for a continuous purification process.
  • In turn, such vaccines can be purified and produced with higher yields at optimal cost.
  • With this new approach, we aim to fine-tune our platform and manufacture vaccines and therapeutics with superior efficacy on a global scale."

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Retrieved on: 
Wednesday, November 30, 2022

As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.

Key Points: 
  • As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.
  • Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023.
  • ONCR-021 is Oncorus lead candidate from its self-amplifying RNA platform intended to allow for intravenous (IV) administration.
  • At Oncorus, we are focused on driving innovation in RNA medicines by developing next-generation immunotherapies to stimulate the immune system and transform outcomes for cancer patients.

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Retrieved on: 
Wednesday, November 30, 2022

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

Key Points: 
  • The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.
  • BioNTech has the option to license global development and commercialization rights to these programs at the development candidate stage.
  • The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules.
  • BioNTech will fund all discovery, research and development activities, including Ryvus discovery and research activities under the multi-target research collaboration.

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Retrieved on: 
Tuesday, November 29, 2022

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

Key Points: 
  • NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Envisagenics , an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).
  • The multi-year collaboration will leverage Envisagenics' SpliceCore AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline.
  • Envisagenics, an AI-driven biotech that focuses on RNA splicing diseases, announced a research collaboration with BMS.
  • "Our SpliceCore platform, coupled with Bristol Myers Squibb's expertise, has the potential to accelerate target identification, transform modern drug development, and improve patient outcomes."

Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform

Retrieved on: 
Tuesday, November 29, 2022

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.

Key Points: 
  • Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.
  • As part of the grant, Touchlight will also be investigating the performance of doggybone DNA for therapeutic monoclonal antibody production.
  • Karen Fallen, CEO of Touchlight, commented: This grant is further evidence of the potential of our doggybone DNA platform.
  • We are excited to start the program, which could potentially demonstrate that the doggybone DNA platform can support a rapid, scalable, durable and thermostable vaccine solution for future pandemic response.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022

Retrieved on: 
Monday, November 28, 2022

SAN DIEGO, Nov. 28, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs)  will be presenting at the Emerging Growth Conference on November 30, 2022 (https://emerginggrowth.com/conference/).

Key Points: 
  • Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time interactive presentation at the Emerging Growth Conference.
  • "We plan to use this time to update our shareholders on our CAR T-cell development program," says Dr. David Koos, CEO and Chairman of the Company.
  • Regen BioPharma, Inc. will be presenting from 1:45 - 2:00 Eastern time on Wednesday, November 30, 2022.
  • Please register here to ensure you are able to attend the conference and receive any updates that are released https://goto.webcasts.com/starthere.jsp?ei=1575088&tp_key=b1fead5049&sti... .

GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022

Retrieved on: 
Monday, November 28, 2022

ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.

Key Points: 
  • ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.
  • He will also discuss GeoVaxs COVID-19 vaccine, GEO-CM04S1, which is currently in two Phase 2 clinical trials, one as a more potent primary vaccine for immunocompromised patients and the other trial as a booster vaccine for healthy patients who have previously received an mRNA vaccine.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the worlds most threatening infectious diseases.
  • GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.